Jessica Konen

Dr. Jessica Konen

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2024 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
Jessica KonenJessica Konen
Jessica Konen
HWHaoyi Wu
Haoyi Wu
DGDon L. Gibbons
Don L. Gibbons

1 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Jessica KonenJessica Konen
Jessica Konen
BRB. Leticia Rodriguez
B. Leticia Rodriguez
HWHaoyi Wu
Haoyi Wu
JFJared Joseph-Alan Fradette
Jared Joseph-Alan Fradette
LGLaura Gibson
Laura Gibson
DGDon L. Gibbons
Don L. Gibbons
Non–small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are immunologically warm tumors with partial responsiveness to anti–PD-(L)1 blockade; however, most patients observe little or no durable clinical benefit. To identify novel tumor-driven resistance mechanisms, we developed a panel of KP murine lung cancer models with intrinsic resistance to anti–PD-1 and queried differential gene expression between these tumors and anti–PD-1–sensitive tumors. We found that the enzyme autotaxin (ATX), and the metabolite it produces, lysophosphatidic acid (LPA), were significantly upregulated in resistant tumors and that ATX directly modulated antitumor immunity, with its expression negatively correlating with total and effector tumor-infiltrating CD8+ T cells. Pharmacological inhibition of ATX, or the downstream receptor LPAR5, in combination with anti–PD-1 was sufficient to restore the antitumor immune response and efficaciously control lung tumor growth in multiple KP tumor models. Additionally, ATX was significantly correlated with inflammatory gene signatures, including a CD8+ cytolytic score in multiple lung adenocarcinoma patient data sets, suggesting that an activated tumor-immune microenvironment upregulates ATX and thus provides an opportunity for cotargeting to prevent acquired resistance to anti–PD-1 treatment. These data reveal the ATX/LPA axis as an immunosuppressive pathway that diminishes the immune checkpoint blockade response in lung cancer.

16 May 2024 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
Ruth NussinovRuth Nussinov
Ruth Nussinov
TWThomas Weichhart
Thomas Weichhart
ZDZodwa Dlamini
Zodwa Dlamini
DGDon L. Gibbons
Don L. Gibbons
Isabelle Van SeuningenIsabelle Van Seuningen
Isabelle Van Seuningen
HJHuai-Qiang Ju
Huai-Qiang Ju

1 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TKTala O. Khatib
Tala O. Khatib
AAAngelica M. Amanso
Angelica M. Amanso
BPBrian Pedro
Brian Pedro
CKChristina M. Knippler
Christina M. Knippler
ESEmily R. Summerbell
Emily R. Summerbell
AMAdam I. Marcus
Adam I. Marcus
Numerous techniques have been employed to deconstruct the heterogeneity observed in normal and diseased cellular populations, including single cell RNA sequencing, in situ hybridization, and flow cytometry. While these approaches have revolutionized our understanding of heterogeneity, in isolation they cannot correlate phenotypic information within a physiologically relevant live-cell state, with molecular profiles. This inability to integrate a historical live-cell phenotype, such as invasiveness, cell:cell interactions, and changes in spatial positioning, with multi-omic data, creates a gap in understanding cellular heterogeneity. We sought to address this gap by employing lab technologies to design a detailed protocol, termed Spatiotemporal Genomics and Cellular Analysis (SaGA), for the precise imaging-based selection, isolation, and expansion of phenotypically distinct live-cells. We begin with cells stably expressing a photoconvertible fluorescent protein and employ live cell confocal microscopy to photoconvert a user-defined single cell or set of cells displaying a phenotype of interest. The total population is then extracted from its microenvironment, and the optically highlighted cells are isolated using fluorescence activated cell sorting. SaGA-isolated cells can then be subjected to multi-omics analysis or cellular propagation for in vitro or in vivo studies. This protocol can be applied to a variety of conditions, creating protocol flexibility for user-specific research interests. The SaGA technique can be accomplished in one workday by non-specialists and results in a phenotypically defined cellular subpopulation for integration with multi-omics techniques. We envision this approach providing multi-dimensional datasets exploring the relationship between live-cell phenotype and multi-omic heterogeneity within normal and diseased cellular populations.

2 June 2026
Verified
Other
Open access
NHNatalie K. Horvat
Natalie K. Horvat
MSMyritney Saint-Cloud
Myritney Saint-Cloud
RMRaihaanah Bint Abdullah Muslim
Raihaanah Bint Abdullah Muslim
YTYanhua Tian
Yanhua Tian
BRB. Leticia Rodriguez
B. Leticia Rodriguez
Jessica KonenJessica Konen
Jessica Konen
Table S5. In silico analysis of conserved miRNA targets in the 3'UTR of mouse and human ATX using TargetScan.org

2 June 2026
Verified
Other
Open access
NHNatalie K. Horvat
Natalie K. Horvat
MSMyritney Saint-Cloud
Myritney Saint-Cloud
RMRaihaanah Bint Abdullah Muslim
Raihaanah Bint Abdullah Muslim
YTYanhua Tian
Yanhua Tian
BRB. Leticia Rodriguez
B. Leticia Rodriguez
Jessica KonenJessica Konen
Jessica Konen
Table S3. Differentially expressed genes in the malignant cell cluster in PD1R1 versus 344SQ tumors.